37 results about "Trypsinogen" patented technology

The present invention relates to novel Prolipase-Bovine trypsinogen (PLBTR) fusion proteins, the genes encoding them, and the production and uses thereof. More specifically, the present invention relates to methods of producing in optimal quantities PLBTR fusion proteins which comprise a heterologous polypeptide which is normally susceptible to autocatalytic activity. More particularly, the present invention relates to fusion proteins which comprise an heterologous polypeptide, such as a serine protease, fused to a lipase signal sequence, which can be expressed by recombinant host cells in desired amounts. The present invention further relates to polynucleotides encoding such fusion proteins, to expression vectors for expression of such fusion proteins, to host cells transformed with such polynucleotides / vectors, and to methods of generating such fusion proteins.

The invention discloses the application of mogroside IIE in preparing trypsin inhibitors, and belongs to the technical field of medicines. After a long period of extensive trials, the inventor of thepresent application finds that the mogroside IIE can inhibit the activity of trypsin at the acinar cell background, and the inhibition has dependence on time and concentration. In addition, the mogroside IE can inhibit the activation of trypsinogen by an acute pancreatitis inducer-cerulein. At the same time, that the mogroside IE inhibits the activation of the trypsinogen is related to cathepsin B, so that the mogroside IE can be used to prepare trypsin inhibitors.

A preparing method of high-purity trypsin is disclosed. The preparing method includes following steps: (1) dissolving a crude product, (2) inactivating viruses by a low-pH incubation method, (3) purifying by hydrophobic chromatography, (4) performing zymogen activation, (5) purifying by affinity chromatography, (6) desalting an eluate, (7) performing membrane filtration to remove the viruses and (8) performing vacuum freeze-drying to obtain the high-purity trypsin. According to the preparing method, the hydrophobic chromatography is adopted to purify the zymogen of the trypsin, the trypsin is purified by the affinity chromatography after the zymogen activation, a process is simple and convenient, and the high-purity high-titer trypsin can be obtained.

The invention provides a production technology of bovine trypsin. By means of a gene recombination technology, bovine trypsinogen or inclusion body protein of bovine trypsinogen fusion protein are expressed out in escherichia coli, and then acidizing is carried out to denature and renature the inclusion body protein into folded bovine trypsinogen or bovine trypsinogen fusion protein. By the adoption of a prokaryotic expression system, the expression quantity is high, denaturation, renaturation and follow-up steps are simple and easy to implement, and the technological cost is low. The prepared bovine trypsin with activity can be used for production of recombinant human insulin and insulin analogues.

Pharmaceutical composition containing a mixture of proenzymes and enzymes, containing proenzymes trypsinogen and chymotrypsinogen and enzymes α-amylase and lipase as active substances, and one or more pharmaceutically acceptable excipients, for simultaneous, separate and subsequent administration of the composition in parenteral or transmucosal way, the composition has anti-proliferative and anti-metastatic effects to cancer tumours and is intended for therapeutic, prophylactic and anti-metastatic use in mammals.

The invention discloses a trypsinogen-2 content detection kit and a preparation method thereof. The detection kit consists of reagent I and reagent II which are independent of each other, wherein the reagent I comprises the following components: a biological buffer, a preservative, inorganic salt and water; the reagent II comprises the following components: latex granules coated by trypsinogen-2 antibody, the biological buffer, the preservative and water. The trypsinogen-2 content detection kit adopts the latex granules with the particle size of 100-300nm to prepare the latex granules coated by the trypsinogen-2 antibody, thus effectively guaranteeing the sensitivity of the kit, the detection linearity range, the measurement value accuracy and the bottle opening stability; furthermore, the latex granules coated by the antibody are prepared by a chemical cross-linking method, so that the combination stability between the antibody and the latex granules can be guaranteed, and the stability of the detection kit is improved. The detection kit has the advantages of being good in stability, high in sensitivity, high in specificity, simple and convenient to operate, etc.